Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Leukemia, Myeloid, Acute 5Myelodysplastic Syndromes 4Leukemia, Myelomonocytic, Chronic 3Thrombocythemia, Essential 1Recurrence 1Primary Myelofibrosis 1Preleukemia 1Polycythemia Vera 1Neoplasm, Residual 1Myeloproliferative Disorders 1Melanoma 1Leukemia, Myeloid 1Leukemia 1Hematologic Diseases 1Glioblastoma 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Bone Marrow Diseases 1

Interventions

Temozolomide 393Radiotherapy 196Bevacizumab 156Radiation 77Magnetic Resonance Spectroscopy 68Lomustine 47Surgical Procedures, Operative 42Carmustine 41pembrolizumab 39Irinotecan 38Nivolumab 32Specimen Handling 27Carboplatin 27Radiosurgery 24Erlotinib Hydrochloride 24Chemotherapy, Adjuvant 23Radiotherapy, Intensity-Modulated 22Drug Therapy 21Cyclophosphamide 20Aminolevulinic Acid 20O(6)-benzylguanine 17sargramostim 16Radiotherapy, Conformal 15temsirolimus 14Granulocyte-Macrophage Colony-Stimulating Factor 14Everolimus 14Vorinostat 13Sorafenib 13poly ICLC 12atezolizumab 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Glioblastoma × sabatolimab × Clear all
NCT03961971 2026-04-23

Trial of Anti-Tim-3 in Combination With Anti-PD-1 and SRS in Recurrent GBM

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1 Active not recruiting
16 enrolled
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡